These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
169 related items for PubMed ID: 2929586
1. Long-term effect of splenectomy on transfusion requirements in thalassemia major. Cohen A, Gayer R, Mizanin J. Am J Hematol; 1989 Apr; 30(4):254-6. PubMed ID: 2929586 [Abstract] [Full Text] [Related]
2. Intensive iron chelation therapy in beta-thalassemia major: some effects on iron metabolism and blood transfusion dependence. Silvestroni E, Bianco I, Graziani B, Lerone M, Valente M, Congedo P, Ponzini D, Costantini S. Acta Haematol; 1982 Apr; 68(2):115-23. PubMed ID: 6812366 [Abstract] [Full Text] [Related]
3. Chelation therapy in beta-thalassemia major. III. The role of splenectomy in achieving iron balance. Graziano JH, Piomelli S, Hilgartner M, Giardina P, Karpatkin M, Andrew M, LoIacono N, Seaman C. J Pediatr; 1981 Nov; 99(5):695-9. PubMed ID: 7299540 [Abstract] [Full Text] [Related]
10. Treatment of iron overload in Cooley's anemia. Cohen A, Mizanin J, Schwartz E. Ann N Y Acad Sci; 1985 Nov; 445():274-81. PubMed ID: 3860130 [No Abstract] [Full Text] [Related]
11. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A, Cnaan A. Haematologica; 2004 Oct; 89(10):1187-93. PubMed ID: 15477202 [Abstract] [Full Text] [Related]
12. High-dose intravenous chelation therapy with deferoxamine. Cohen A, Mizanin J, Schwartz E. Prog Clin Biol Res; 1989 Oct; 309():125-31. PubMed ID: 2780746 [No Abstract] [Full Text] [Related]
13. Partial splenectomy in homozygous beta thalassaemia. de Montalembert M, Girot R, Revillon Y, Jan D, Adjrad L, Ardjoun FZ, Belhani M, Najean Y. Arch Dis Child; 1990 Mar; 65(3):304-7. PubMed ID: 2334210 [Abstract] [Full Text] [Related]
16. Bone metabolism in thalassemia. Garofalo F, Piga A, Lala R, Chiabotto S, Di Stefano M, Isaia GC. Ann N Y Acad Sci; 1998 Jun 30; 850():475-8. PubMed ID: 9668589 [No Abstract] [Full Text] [Related]
17. [Thalassemia major: chelating therapy with deferoxamine]. Abreu de Miani MS, Sanchis de Herrlein MS, Peñalver JA. Medicina (B Aires); 1985 Jun 30; 45(3):231-4. PubMed ID: 3841934 [No Abstract] [Full Text] [Related]
18. [Monitoring and appraisal of the effects of blood transfusion and iron chelation in thalassemia major]. Girot R, Triadou P, Bories D, Jeannel F, Thevenin M, Rymer JC. Nouv Rev Fr Hematol (1978); 1982 Jun 30; 24(5):281-7. PubMed ID: 7167380 [Abstract] [Full Text] [Related]
19. [Our experience with "supertransfusive" treatment of homozygous beta-thalassemia]. Esposito L, Ferrara M, Ponte G. Pediatria (Napoli); 1983 Jun 30; 91(1):27-30. PubMed ID: 6889088 [No Abstract] [Full Text] [Related]
20. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Delea TE, Edelsberg J, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD. Transfusion; 2007 Oct 30; 47(10):1919-29. PubMed ID: 17880620 [Abstract] [Full Text] [Related] Page: [Next] [New Search]